2026-02-10, 2:43:14 p.m.
TORONTO, February 10, 2026 — Leads & Copy —
PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB:MDXXF) has announced changes to its Board of Directors, effective February 9, 2026.
Dr. Malik Slassi has resigned from the board, and Mr. Lennie Ryer, CPA, CA, of Montreal, has been appointed as a new director.
PharmAla Biotech is a biotechnology company focused on researching, developing, and manufacturing LaNeo™ MDMA and novel MDMA derivatives (MDXX class molecules).
Nicholas Kadysh, CEO of PharmAla Biotech, expressed gratitude for Dr. Slassi’s support over the past four years. He also welcomed Mr. Ryer to the board, citing his experience and expertise as valuable for the company’s next phase of development.
Mr. Ryer is a seasoned financial executive with extensive experience in corporate finance, governance, and strategic leadership. He has held senior roles, including Chief Financial Officer and Vice President of Finance, in pharmaceutical, biotechnology, and technology companies. He was also Managing Partner of a major public accounting firm, specializing in mergers and acquisitions, taxation, and capital markets.
Mr. Ryer’s background includes guiding companies through transitions to public markets and leading significant equity and debt financings. He holds a Bachelor of Commerce in Finance and a Public Accountancy degree from McGill University and is a Chartered Professional Accountant (CPA, CA).
PharmAla Biotech focuses on alleviating the global backlog of clinical-grade MDMA to enable clinical trials and commercial sales in selected jurisdictions and developing novel drugs in the same class. The company is currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla’s research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate.
PharmAla operates under the principle that success in the psychedelics industry requires excellent relationships with regulators.
Source: PharmAla Biotech Holdings Inc.
